sions, characteristic of herpes group virus infection (Fig. 1).

Electron microscopic examination of thin sections of liver, negatively stained, showed the presence of a virus of the herpes group (Fig. 2). Herpes simplex virus was recovered in tissue cultures inoculated with lung, kidney, brain, and liver tissue. In this case, the only clinical sign which suggested a herpetic infection was the transient vesicular lesions on the lingula but the absence of antibodies to herpes simplex virus was taken, apparently reasonably, as strong evidence that this virus was not contributing to her clinical condition. For this reason, no antiviral treatment was given. We have since become aware of Flewett’s report of an adult with herpetic hepatitis in whom serology was unhelpful, the correct diagnosis being made on liver biopsy and electron microscopy.

The case of this unfortunate woman leads us to two conclusions. Firstly, a liver biopsy should be very helpful in reaching an early diagnosis in patients under immunosuppression who present with an otherwise undiagnosable deterioration in their clinical state and liver function tests. Secondly, in agreement with Walker and his colleagues, we consider that the administration of acyclovir, even in the absence of supporting conventional viral diagnostic evidence, may be a life-saving measure. The importance of attempting a histological diagnosis and the feasibility of administering acyclovir “blindly” are consequences of the efficacy and relative non-toxicity of this antiviral drug.

References


Serum antibodies to hepatitis B virus in alcoholic liver disease

Conflicting data have been reported concerning the higher prevalence of serum antibody to hepatitis B virus antigens in patients with alcoholic cirrhosis. We have compared 60 hospital patients with biopsy-proven alcoholic cirrhosis (mean age 46 yr ± 10 SD; 45 men) with an age- and sex-matched hospital control population, a mixed group of HBsAg-negative chronic alcoholic cirrhosis (HBsAg-veCAG) (47 ± 19 yr; 6 men) and 32 renal unit patients (43

References


Urine cyclic nucleotides in cancer and other conditions

I read with interest the paper by GA Turner et al in your issue of August 1982. I would like to give some additional remarks about the levels of cyclic nucleotides in urines of cancer patients, especially cytosine monophosphate (CMP).

We have studied the cyclic nucleotide contents of leucocytes and urines of healthy volunteers, of patients with solid tumours and with leukaemias. We found that the concentration of cyclic CMP is always lower than that of cyclic GMP or cyclic AMP; however, in urines, the concentrations of the three nucleotides are higher in patients than in normal controls, but the greatest difference is observed between the cyclic CMP concentrations of acute leukaemia patients and controls. The cyclic CMP concentration is higher in monoblastic cells and in leucocytes from patients with solid tumours.

High cyclic CMP concentrations are associated only with acute leukaemias. This suggests that cyclic CMP could be a biochemical marker of hematopoietic stem cell malignancy.

Y CARCASSONE

Department of Hematology

Institut Paoli-Calmettes

Marseille

France
Letters to the Editor

Hepatitis B antibodies in patients with alcoholic cirrhosis, hospital controls, HBsAg-negative chronic cirrhosis (HBsAg-veCAC) and renal unit patients

<table>
<thead>
<tr>
<th>Group</th>
<th>Total of patients</th>
<th>anti-HBs alone</th>
<th>anti-HBc alone</th>
<th>anti-HBc and anti-HBs</th>
<th>Total with antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholic cirrhosis</td>
<td>60</td>
<td>13</td>
<td>9</td>
<td>21</td>
<td>43</td>
</tr>
<tr>
<td>HBsAg-veCAC</td>
<td>27</td>
<td>1</td>
<td>6</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>Renal unit</td>
<td>32</td>
<td>4</td>
<td>5</td>
<td>12</td>
<td>21</td>
</tr>
<tr>
<td>Hospital controls</td>
<td>60</td>
<td>3</td>
<td>1</td>
<td>18</td>
<td>22</td>
</tr>
</tbody>
</table>

± 11 yr; 15 subjects). A history of blood transfusion, previous jaundice, tattooing, or needle injections were excluded in the alcoholic cirrhosis group and hospital control group. In the HBsAg-veCAC group, six patients gave a previous history of jaundice, one a history of blood transfusion; in the other five patients a post-hepatitis B chronic liver disease could not be excluded.

Serum samples from each group were examined by RIA method (Abbott) for HBsAg, and antibody to HBsAg and HBcAg.

All sera were HBsAg-negative.

Our antibody results are shown in the Table. These findings indicate that the prevalence of hepatitis B virus antibodies ($x^2$ test with Yates' correction) was significantly increased in the alcoholic cirrhosis group when compared with the hospital control group ($p < 0.001$); in HBsAg-veCAC and renal unit patients there was no significant difference from alcoholic cirrhosis patients.

The high prevalence of serum antibodies to hepatitis B virus in alcoholic cirrhosis as well as in renal unit patients has been confirmed in this survey in the Milan area.

**Microbiological safety tests**

In a recent paper “Guidelines for the evaluation of instruments used in haematology laboratories” the authors recommend that “instruments should be tested for the production during normal operations of potentially infected droplets or aerosol”. In describing how this should be done they state correctly that the most sensitive method requires the use of a biological tracer such as a bacterial spore and the services of an experienced microbiologist. They then go on to say that an estimate of the microbiological hazard can be obtained by using a fluorescent chemical marker and examining sheets of filter paper placed around the equipment under ultraviolet light for evidence of contamination. There is an implication that this procedure is an adequate substitute for the use of a biological tracer to assess any microbiological hazard that might arise from the equipment being tested. This is a dangerous assumption.

Work carried out in this laboratory to assess the sensitivity of various tracer materials added to human serum showed that microbiological challenge materials, normally used at a concentration of $1 \times 10^{10}$ cells/ml could be detected when completely negative results were found using 1% (wt/vol) sodium fluorescein. In these tests a sensitive fluorometer (Locarte Co, London) was used to measure fluorescence. The lower limit for detection of the biological tracers was 2500 times smaller than for the fluorescein solution. In a comparison of a spore tracer using settle plates, and sodium fluorescein and filter paper discs of a comparable area, up to 100 bacterial colonies were present on the settle plates: the filter papers were uniformly negative when examined under ultraviolet light. There are numerous examples of similar failure to detect contamination with a fluorescent marker when the use of a microbiological tracer showed heavy contamination.

When we consider the hazard from small airborne particles in the size range likely to be inhaled and retained in the lungs, the situation is a good deal worse. The small particles have a low settling rate even in still air so relatively few are likely to be deposited on filter paper surrounding the equipment. Any that do settle will probably be too small to visualise by eye when the paper is examined under ultraviolet light. The collection of small airborne particles calls for the use of efficient air sampling equipment such as that used in this laboratory.

As there is now considerable interest in drawing up international standards by bodies such as the European Committee for Clinical Laboratory Standards (ECCLS) and the International Standards Organisation (ISO) it is likely that papers such as that of Shipton, England and Kennedy will be used in formulating new standards. For this reason it is important that it should be clearly stated that the use of fluorescent markers, while useful for rapidly detecting gross contamination on surfaces, should not be relied on for a proper assessment of microbiological hazards from equipment or laboratory techniques.

GJ HARPER

Environmental Microbiology and Safety
Reference Laboratory,
Public Health Laboratory Service,
Centre for Applied Microbiology and
Research,
Porton Down,
Salisbury,
Wiltshire.

References


References


Serum antibodies to hepatitis B virus in alcoholic liver disease.

R Natangelo, A Monarca, A Bastia, L Adelasco and G Croce

doi: 10.1136/jcp.36.1.116-b

Updated information and services can be found at:
http://jcp.bmj.com/content/36/1/116.2.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/